Birdwatch Note
2024-05-25 21:39:53 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
O estudo faz uma comparação dos resultados em pacientes com diabetes e doença renal crônica. E a dosagem recomendada era p/ diabéticos, conforme a bula, e não para obesidade, durante um período de 3 anos. Os benefícios foram confirmados exclusivamente nesse grupo de pacientes. www.washingtonpost.com/health/2024/05/24/ozempic-kidney-disease-study
Written by 64D33DD1166907ED385AE9A9B59A31E672C37407388728FD2FB2DEC6EF4C82BB
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1794454970634555623
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1794483552173662356
- noteId - 1794483552173662356
- participantId -
- noteAuthorParticipantId - 64D33DD1166907ED385AE9A9B59A31E672C37407388728FD2FB2DEC6EF4C82BB Participant Details
- createdAtMillis - 1716673193388
- tweetId - 1794454970634555623
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 1
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- O estudo faz uma comparação dos resultados em pacientes com diabetes e doença renal crônica. E a dosagem recomendada era p/ diabéticos, conforme a bula, e não para obesidade, durante um período de 3 anos. Os benefícios foram confirmados exclusivamente nesse grupo de pacientes. www.washingtonpost.com/health/2024/05/24/ozempic-kidney-disease-study
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2024-05-25 21:39:53 UTC (1716673193388) |
2024-05-25 23:10:06 UTC (1716678606572) |
CURRENTLY_RATED_HELPFUL | 2024-05-26 01:23:46 UTC (1716686626098) |
CURRENTLY_RATED_HELPFUL | 2024-05-25 23:10:06 UTC (1716678606572) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
| rated at | rated by | |
| 2024-05-25 18:51:32 -0500 | Rating Details | |
| 2024-05-25 18:09:56 -0500 | Rating Details | |
| 2024-05-25 18:00:23 -0500 | Rating Details | |
| 2024-05-25 17:53:18 -0500 | Rating Details | |
| 2024-05-25 17:45:54 -0500 | Rating Details | |
| 2024-05-25 17:43:49 -0500 | Rating Details | |
| 2024-05-25 17:42:41 -0500 | Rating Details | |
| 2024-05-25 17:32:57 -0500 | Rating Details | |
| 2024-05-25 17:24:20 -0500 | Rating Details | |
| 2024-05-25 17:19:31 -0500 | Rating Details | |
| 2024-05-25 17:10:14 -0500 | Rating Details | |
| 2024-05-25 17:05:32 -0500 | Rating Details | |
| 2024-05-25 17:02:30 -0500 | Rating Details | |
| 2024-05-25 16:59:16 -0500 | Rating Details | |
| 2024-05-25 16:56:07 -0500 | Rating Details | |
| 2024-05-25 16:51:30 -0500 | Rating Details | |
| 2024-05-25 16:44:47 -0500 | Rating Details | |
| 2024-05-25 16:42:43 -0500 | Rating Details | |
| 2024-05-26 08:52:42 -0500 | Rating Details | |
| 2024-05-26 07:40:29 -0500 | Rating Details | |
| 2024-05-25 22:56:02 -0500 | Rating Details | |
| 2024-05-25 22:07:27 -0500 | Rating Details | |
| 2024-05-25 20:12:12 -0500 | Rating Details | |
| 2024-05-25 20:08:01 -0500 | Rating Details | |
| 2024-05-25 18:16:52 -0500 | Rating Details | |
| 2024-05-25 18:04:02 -0500 | Rating Details | |
| 2024-05-25 17:56:51 -0500 | Rating Details | |
| 2024-05-25 17:49:22 -0500 | Rating Details | |
| 2024-05-25 17:35:09 -0500 | Rating Details | |
| 2024-05-25 17:34:21 -0500 | Rating Details | |
| 2024-05-25 17:31:48 -0500 | Rating Details | |
| 2024-05-25 17:21:25 -0500 | Rating Details | |
| 2024-05-25 17:18:24 -0500 | Rating Details | |
| 2024-05-25 17:17:28 -0500 | Rating Details | |
| 2024-05-25 17:12:33 -0500 | Rating Details | |
| 2024-05-25 17:10:21 -0500 | Rating Details | |
| 2024-05-25 17:08:42 -0500 | Rating Details | |
| 2024-05-25 16:40:35 -0500 | Rating Details | |
| 2024-05-27 07:17:46 -0500 | Rating Details | |
| 2024-05-27 20:30:09 -0500 | Rating Details | |
| 2024-05-27 15:12:29 -0500 | Rating Details | |
| 2024-05-27 06:40:48 -0500 | Rating Details | |
| 2024-05-26 10:51:46 -0500 | Rating Details | |
| 2024-05-26 10:21:30 -0500 | Rating Details | |
| 2024-05-26 08:46:46 -0500 | Rating Details | |
| 2024-05-26 08:20:45 -0500 | Rating Details | |
| 2024-05-31 19:22:58 -0500 | Rating Details | |
| 2024-05-28 22:31:59 -0500 | Rating Details | |
| 2024-05-27 22:02:37 -0500 | Rating Details | |
| 2024-05-26 17:33:01 -0500 | Rating Details | |
| 2024-05-26 11:53:56 -0500 | Rating Details | |
| 2024-05-26 10:05:49 -0500 | Rating Details | |
| 2024-05-26 09:07:26 -0500 | Rating Details | |
| 2024-05-25 23:49:47 -0500 | Rating Details | |
| 2024-05-25 21:58:05 -0500 | Rating Details | |
| 2024-05-25 20:28:33 -0500 | Rating Details | |
| 2024-05-25 20:08:28 -0500 | Rating Details | |
| 2024-05-25 19:38:52 -0500 | Rating Details | |
| 2024-05-25 19:36:25 -0500 | Rating Details | |
| 2024-05-25 19:34:42 -0500 | Rating Details | |
| 2024-05-25 19:16:41 -0500 | Rating Details | |
| 2024-05-25 18:37:43 -0500 | Rating Details | |
| 2024-05-25 18:21:13 -0500 | Rating Details | |
| 2024-05-25 18:20:23 -0500 | Rating Details | |
| 2024-05-25 18:09:40 -0500 | Rating Details | |
| 2024-05-25 17:58:35 -0500 | Rating Details | |
| 2024-05-25 17:54:18 -0500 | Rating Details | |
| 2024-05-25 17:48:07 -0500 | Rating Details | |
| 2024-05-25 17:34:59 -0500 | Rating Details | |
| 2024-05-25 17:29:15 -0500 | Rating Details | |
| 2024-05-25 17:27:21 -0500 | Rating Details | |
| 2024-05-25 17:27:00 -0500 | Rating Details | |
| 2024-05-25 17:23:03 -0500 | Rating Details | |
| 2024-05-25 17:18:01 -0500 | Rating Details | |
| 2024-05-25 17:10:16 -0500 | Rating Details | |
| 2024-05-25 16:59:07 -0500 | Rating Details | |
| 2024-05-25 16:52:39 -0500 | Rating Details | |
| 2024-05-25 16:46:53 -0500 | Rating Details | |
| 2024-06-01 08:19:23 -0500 | Rating Details | |
| 2024-06-15 07:27:25 -0500 | Rating Details |